Boehringer Ingelheim and Eli Lilly & Company launch type 2 diabetes educational game, "Complications Combat"

Boehringer IngelheimBoehringer Ingelheim and Eli Lilly & Company have launched an educational digital game for type 2 diabetes called Complications Combat. The game, available for desktop and iPad users, is designed to raise awareness of the many complications associated with type 2 diabetes and the challenges physicians and patients face when considering and managing these on a daily basis.

"The aim and design of the game is simple," said Arnd Prilipp, Launch and Established Products CVM Boehringer Ingelheim. "However, effective management of type 2 diabetes and its complications is not. To simulate this, players are tasked with simultaneously saving the healthy lifestyle items whilst combating the many complications - and it is not easy."

The objective of the game is to effectively manage type 2 diabetes and its complications by clicking or swiping the complications and 'friends', which are the healthy steps for managing the condition, to the correct side of the screen to maintain optimal patient health for as long as possible. During the course of the game, the user learns about the diverse range of complications that can be associated with type 2 diabetes and also about positive lifestyle choices that can help combat the progression of the disease. As the game becomes increasingly difficult, the user learns just how challenging it can be for physicians and patients to take all of these complications and lifestyle choices into consideration at the same time.

Uncontrolled type 2 diabetes can lead to hyperglycaemia which, if untreated in the long-term, can cause serious medical complications in all parts of the body.(1) Diabetes-related complications include cardiovascular disease, stroke, kidney disease, eye problems and foot ulcers.(2)

Complications Combat can be played at www.complicationscombat.com and iPad users can download the free touchscreen app at https://itunes.apple.com/hk/app/complication-combat-how-long/id640173022?mt=8.

About Diabetes
An estimated 371 million people worldwide have Type 1 and Type 2 Diabetes.(1) Type 2 Diabetes is the most common type, accounting for an estimated 90% of all diabetes cases.(3) Diabetes is a chronic disease that occurs when the body either does not properly produce, or use, the hormone insulin.(4)

Boehringer Ingelheim and Eli Lilly and Company
In January 2011, Boehringer Ingelheim and Eli Lilly and Company announced an alliance in the field of diabetes that centers on three compounds representing several of the largest treatment classes. This alliance leverages the companies' strengths as two of the world's leading pharmaceutical companies, combining Boehringer Ingelheim's solid track record of research-driven innovation and Lilly's innovative research, experience, and pioneering history in diabetes. By joining forces, the companies demonstrate commitment in the care of patients with diabetes and stand together to focus on patient needs.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more than 46,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

In 2012, Boehringer Ingelheim achieved net sales of about 14.7 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 22.5% of its net sales.

About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organisations. Headquartered in Indianapolis, IN, Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs.

1. International Diabetes Federation. Available at: www.idf.org. Last accessed January 2013.
2. Dang CN BA. Changing perspectives in diabetic foot ulcer management. Int J Low Extrem Wounds 2003;2(1)::4-12.
3. World Health Organization. Fact Sheet No. 312 Diabetes 2009 [cited 2013 January 2013]; Available from: http://www.who.int/mediacentre/factsheets/fs312/en/index.html#
4. International Diabetes Federation. What is Diabetes? IDF Diabetes Atlas. 2011; (5th Edition).

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

China's out of control 'silent killer' affects one…

More than one-third of adults in China have high blood pressure - often dubbed the "silent killer" for its lack of symptoms - but only about one in 20 have the condition ...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

Efficacy and safety maintained in patients who swi…

Boehringer Ingelheim today announced one-year data from VOLTAIRE®-RA, a pivotal Phase III clinical trial comparing Cyltezo® (adalimumab-adbm) and reference product Humira...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]